Long-term aspirin use linked to lower risk for gastrointestinal tract cancers
Regular low doses of aspirin for at least six years was associated with a modestly reduced overall risk for cancer, primarily due to a lower risk for gastrointestinal tract cancer, especially colorectal cancers, according to an article published online by JAMA Oncology.
The U.S. Preventive Services Task Force recently recommended aspirin to prevent colorectal cancer and cardiovascular disease among many U.S. adults. However, the association of aspirin on the risk of other types of cancer and what additional effect aspirin might have in the context of screening remain unclear.
Andrew T. Chan, M.D., M.P.H., of the Massachusetts General Hospital, Boston, and coauthors looked at the association of aspirin with cancer among 135,965 women and men enrolled in two large U.S. studies of health care professionals.
The authors documented 20,414 cancers among 88,084 women and 7,571 cancers among 47,881 men during a 32-year follow-up. Regular use of aspirin two times or more per week was associated with a 3 percent lower risk for overall cancers, which was mostly due to a 15 percent lower risk for gastrointestinal tract cancers and a 19 percent lower risk for cancers of the colon and rectum, according to the results.
However, regular use of aspirin was not associated with a lower risk for other major cancers, such as breast, prostate or lung, the authors report.
Study findings suggest that, for the gastrointestinal tract, aspirin may influence additional mechanisms important for the formation of cancer, which may explain the stronger association of aspirin for a lower risk of gastrointestinal cancers.
On a population-wide level, the authors suggest regular aspirin use could prevent 17 percent of colorectal cancers among those who did not undergo lower endoscopy and 8.5 percent of colorectal cancers among those who underwent lower endoscopy.
Limitations to the study include that results of an observational study, such as this, are not as definitive as those of a randomized clinical trial.
"Aspirin may be a potential low-cost alternative to endoscopic CRC [colorectal cancer] screening in resource-limited settings or a complement in settings in which such programs are already implemented, including the general U.S. population, in whom screening adherence remains suboptimal," the study concludes.
(JAMA Oncol. Published online March 3, 2016. doi:10.1001/jamaoncol.2015.6396. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: The study includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Commentary: Aspirin for Cancer Prevention
"Despite these careful analyses, perhaps the most important and unique contributions of this study are the team's assessment of aspirin's potential population-wide impact and its absolute benefits in the context of screening. … This finding is important because it suggests that aspirin use may complement CRC screening and may have an absolute benefit regardless of endoscopy status, a critical insight that few other studies have provided thus far," write Ernest T. Hawk, M.D., M.P.H., of the University of Texas MD Anderson Cancer Center, Houston, and coauthors in a related commentary.
(JAMA Oncol. Published online March 3, 2016. doi:10.1001/jamaoncol.2015.6395. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: The article contains funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Media Advisory: To contact corresponding study author Andrew T. Chan, M.D., M.P.H., call Katie Marquedant at 617 726-0337 or email email@example.com. To contact commentary corresponding author Ernest T. Hawk, M.D., M.P.H., call Clayton R. Boldt, Ph.D. at 713-792-9518 or email firstname.lastname@example.org.
Video and Audio Content: A video and audio report is available under embargo at this link and includes broadcast-quality downloadable video and audio files, B-roll, scripts, and other images. Please email JAMAReport@synapticdigital.com with any questions.
To place an electronic embedded link in your story: Links will be live at the embargo time: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.6396; http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.6395